Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis

Ítems similars

• Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
  per: Balak, Deepak MW, et al.
  Publicat: (2013)
• Treatment of lupus erythematosus with fumaric acid ester derivatives: two case-reports
  per: Balak, Deepak MW, et al.
  Publicat: (2011)
• Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
  per: Cortese, Irene, et al.
  Publicat: (2016)
• Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
  per: Kolb-Mäurer, Annette, et al.
  Publicat: (2015)
• Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review
  per: Zimmermann, Stefanie, et al.
  Publicat: (2014)